The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model by El-Khoury, V et al.
The histone deacetylase inhibitor trichostatin A downregulates
human MDR1 (ABCB1) gene expression by a
transcription-dependent mechanism in a drug-resistant
small cell lung carcinoma cell line model
V El-Khoury
1, G Breuzard
1, N Fourre ´
1 and J Dufer*,1
1Unite ´ Me ´DIAN-CNRS UMR 6142, IFR 53, Faculte ´ de Pharmacie, Universite ´ de Reims Champagne-Ardenne, F-51096 Reims, France
Tumour drug-resistant ABCB1 gene expression is regulated at the chromatin level through epigenetic mechanisms. We examined the
effects of the histone deacetylase inhibitor trichostatin A (TSA) on ABCB1 gene expression in small cell lung carcinoma (SCLC) drug-
sensitive (H69WT) or etoposide-resistant (H69VP) cells. We found that TSA induced an increase in ABCB1 expression in drug-
sensitive cells, but strongly decreased it in drug-resistant cells. These up- and downregulations occurred at the transcriptional level.
Protein synthesis inhibition reduced these modulations, but did not completely suppress them. Differential temporal patterns of
histone acetylation were observed at the ABCB1 promoter: increase in H4 acetylation in both cell lines, but different H3 acetylation
with a progressive increase in H69WT cells but a transient one in H69VP cells. ABCB1 regulations were not related with the
methylation status of the promoter  50GC,  110GC, and Inr sites, and did not result in further changes to these methylation
profiles. Trichostatin A treatment did not modify MBD1 binding to the ABCB1 promoter and similarly increased PCAF binding in both
H69 cell lines. Our results suggest that in H69 drug-resistant SCLC cell line TSA induces downregulation of ABCB1 expression
through a transcriptional mechanism, independently of promoter methylation, and MBD1 or PCAF recruitment.
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The overexpression of the ABCB1 (MDR1) gene product P-
glycoprotein (P-gp) has been identified as an important mediator
of multidrug resistance (MDR) to chemotherapeutic agents, which
can lead to increased tumour resistance and worse prognosis in
cancer patients (Gottesman, 2002; Longley and Johnston, 2005).
Small cell lung carcinoma (SCLC) is usually responsive to
chemotherapy, but long-term survival is rare. Several chemother-
apeutic agents active in SCLC patients (as doxorubicin, etoposide,
or vincristine) are P-gp substrates, raising the question of the
impact of ABCB1 expression in these types of tumours. In patient
samples, good correlations have been reported between increased
ABCB1 expression, lack of response to chemotherapy, and shorter
survival (Holzmayer et al, 1992; Poupon et al, 1993; Savaraj et al,
1997), suggesting that ABCB1 gene expression may play a
significant role in drug resistance in SCLC.
Considerable progress has been made towards the definition of
the regulatory mechanisms that control the expression of ABCB1
gene in tumour cells (for review, see Labialle et al, 2002; Scotto,
2003). The ABCB1 promoter lacks a TATA box and contains an
initiator element (Inr) necessary for its transcription. Like most
TATA-less promoters, ABCB1 promoter contains an inverted
CCAAT box (Y box) close to a  50GC box. These two elements,
where NF-Y, Sp1, and Sp3 factors can bind, form an enhancesome
and recruit the histone acetyltransferase (HAT) PCAF. This HAT
further acetylates histones at the proximal promoter region and
then induces transcriptional activation of ABCB1 gene. Several
other elements have also been described among which a  110GC
box able to bind a repressor factor. Accessibility of ABCB1
promoter elements to their binding factors is regulated at the
chromatin level by epigenetic regulatory mechanisms including
DNA methylation and histones post-translational modifications.
Among these modifications, acetylation of lysine residues of
histone tails by HAT has been correlated with transcriptional
activity, whereas deacetylation mediated by histone deacetylases
(HDACs) has been associated with gene silencing (Grunstein, 1997;
Berger, 2002).
Histone deacetylase inhibitors have been shown to have anti-
tumour effects and a number of them are currently being evaluated
in cancer therapy, either alone or in combination with conven-
tional cytotoxic therapy (Yoo and Jones, 2006). In this regard, the
impact of HDAC inhibition on ABCB1 gene expression seems to be
of critical importance.
We and others showed previously that HDAC inhibition induced
similar proliferation inhibition and apoptotic response in H69
drug-sensitive and drug-resistant cells. This was associated with a
blockade of the cells in the G0/G1 and the G2/M phases of the cycle
in both cell lines (Tsurutani et al, 2003; El-Khoury et al, 2004).
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consequences at the chromatin condensation level in drug-
sensitive and drug-resistant cells (El-Khoury et al, 2004). Such
data could raise questions on the effects of HDAC inhibition on
ABCB1 expression in these cell variants.
In this study, we have utilised the HDAC inhibitor, trichostatin
A (TSA), to investigate the responsiveness of endogenous ABCB1
gene to acetylation states in SCLC H69 cells, either sensitive
(H69WT) or resistant to etoposide (H69VP). This response was
analysed in terms of dependence on transcription, DNA methyla-
tion, or histone acetylation at the promoter level. Moreover, the
role of transcription regulators as PCAF and MBD1 was also
evaluated.
MATERIALS AND METHODS
Chemicals
The HDAC inhibitors TSA and sodium butyrate (NaB), actino-
mycin D (ActD), and cycloheximide (CHX) were purchased from
Sigma-Aldrich (St Quentin-Fallavier, France). All antibodies
against histones and peroxidase-conjugated anti-rabbit secondary
antibody were from Upstate Biotechnology (Lake Placid, NY).
Phycoerythrin-conjugated antibody against P-gp (15D3-PE) was
purchased from BD Biosciences (Grenoble, France), anti-PCAF
antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
and anti-MBD1 antibody from Abcam (Cambridge, UK). All other
chemicals were obtained from standard sources.
Cells
The human small cell lung carcinoma (SCLC) cell line H69 was
obtained from ATCC (HTB-119) and its P-gp-positive multidrug-
resistant variant H69VP selected with etoposide was provided
by Professor Maxwell Sehested (Rigshospitalet, Copenhagen,
Denmark) (Brock et al, 1995). The two cell lines were grown as
previously reported (El-Khoury et al, 2004). The H69VP cells are
about 17-fold resistant to etoposide and 8-fold and 6-fold cross-
resistant to vincristine and doxorubicin, respectively.
Anti-P-gp immunostaining and fluorescence-activated cell
sorting (FACS) analysis
Cells were stained with phycoerythrin-conjugated anti-P-gp
monoclonal antibody 15D3-PE according to the manufacturer’s
instructions. A total of 2 10
4 cells were immediately analysed
on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA,
USA) with an argon laser set at 488nm. Data were analysed with
BD Cell Quest software.
Real-time and classical reverse transcription (RT)–PCR
Total cellular RNA was prepared using the guanidine thiocyanate/
phenol method (Tri Reagent, Sigma). RNA (1mg) was reverse
transcribed into cDNA in a final volume of 20ml using the
ImProm-II Reverse Transcription System Kit (Promega, WS).
Real-time PCR was performed with QuantiTectSYBR-Green PCR
Kit (Qiagen, Courtaboeuf, France) on the LightCycler system
(Roche Diagnostics, Basel, Switzerland) following the recommen-
dation of the manufacturer. The expression levels of ABCB1 mRNA
were normalised against 18S ribosomal RNA level of the same
sample. To detect WTH3 gene expression, classical RT–PCR was
carried out using recombinant Taq polymerase (Invitrogen,
France) on a PCR System Thermal Cycler (Eppendorf, France)
and its expression level was normalised against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA. PCR primers and
conditions are available upon request. Values reported represent
the mean gene expression from at least three separate experi-
ments7s.e.m. Data were analysed using Student’s t-test.
Acid extraction and immunoblotting of histones
Histones acid extraction and immunoblotting analysis were
performed as described previously (El-Khoury et al, 2004).
Antibodies were used at the following dilutions: anti-histone H3
(1:2000), anti-acetylated histone H3 (1:20000), anti-acetylated
histone H4 (1:2000), and anti-dimethylated histone H3 on lysine 9
(H3K9) (1:2000), peroxidase-conjugated anti-rabbit secondary
antibody (1:2000).
Acetic acid-urea-triton (AUT) gel electrophoresis
Acetic acid-urea-triton gel electrophoresis of histones was carried
out following the protocol described previously (El-Khoury et al,
2004).
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay kit from Upstate Biotechnology was used following
the manufacturer’s instructions with the following modifications:
cross-linking with formaldehyde was carried out for 10–20min.
Chromatin was immunoprecipitated with 8mg of either anti-
acetylated histone H3, anti-acetylated histone H4, anti-dimethy-
lated H3K9, anti-PCAF, or with 15ml of anti-MBD1 antibody. Three
regions of the ABCB1 promoter were analysed: a proximal region
(þ292 to þ591), a distal region ( 981 to –817), and the inverted
CCAAT box (Y box) region ( 222 to þ37). In the case of histones
and PCAF analyses, PCR products were resolved on 2% agarose
gels stained with ethidium bromide, and quantitated using
Typhoon 9210 scanner and Image Quant analysis software
(Amersham Biosciences, Orsay, France). For MBD1 analysis,
real-time PCR was carried out. PCR primers and conditions are
available upon request.
Bisulphite treatment of genomic DNA and methylation-
specific PCR
Genomic DNA was isolated using NucleoSpin Tissue kit (Macher-
ey-Nagel, Hoerdt, France) according to manufacturer’s protocol. A
total of 2mg of genomic DNA was denatured in 0.3moll
 1 NaOH
for 15min at 371C. The denaturated DNA was incubated with
0.5mM hydroquinone and 3.1moll
 1 sodium bisulphite (pH 5) for
16h at 501C. DNA was purified using the Wizard DNA clean-up
system (Promega) and desulphonated with 0.3N NaOH at 371C for
15min. DNA was precipitated with ammonium acetate and
ethanol, washed with 70% ethanol, and resuspended in 20ml
distilled water. For methylation-specific PCR analysis, the bisul-
phite-modified DNA samples were amplified by primers specific
for both methylated and unmethylated sequences of the  50GC
and  110GC boxes of the ABCB1 promoter. DNA amounts were
demonstrated in a PCR analysis using a primer set designed to
amplify both the bisulphite-modified methylated and unmethy-
lated sequences of the region including  50GC and  110GC boxes.
PCR primers and conditions are available upon request. PCR
products were analysed in 2% agarose gel stained with ethidium
bromide.
Combined bisulphite restriction analysis (COBRA)
This method enables a quantitative analysis of methylation at
specific gene loci (Xiong and Laird, 1997). Bisulphite-modified
genomic DNA was amplified by PCR. PCR primers sequences of
the Inr region ( 20 to þ172) and PCR conditions are available
upon request. Purified PCR products (192bp) were digested with
restriction enzyme TaqI (Invitrogen), which recognises the TCGA
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of the methylated alleles of the Inr site. DNA samples were
precipitated and electrophoresed in 2.5% agarose gel stained with
ethidium bromide. The intensity of methylated alleles was
calculated by densitometry using Typhoon 9210 scanner and
Image Quant analysis software (Amersham Biosciences).
RESULTS
TSA and NaB induce ABCB1 upregulation in
H69WT-sensitive cells but downregulation in
H69VP-resistant cells
Several studies indicate that ABCB1 gene activity is regulated by
HDACs. To analyse this regulation in drug-sensitive and drug-
resistant cells, H69WT and H69VP cells were exposed to the HDAC
inhibitors TSA and NaB (330nmoll
 1 and 5mmoll
 1 concentra-
tions, respectively) for up to 24h. These concentrations were
shown previously optimal for inhibition of HDACs with minimal
toxicity in these particular cells (El-Khoury et al, 2004).
Trichostatin A and NaB induce significant increases in ABCB1
expression in H69WT cells whose basal expression was extremely
low (Figure 1A, left). This expression appears as early as 8h of
treatment with both drugs (56-fold increase with TSA, P¼0.0005;
35-fold increase with NaB, P¼0.008) and increases after 24h of
treatment (164-fold increase with TSA, P¼0.008; 167-fold increase
with NaB, P¼0.008). On the contrary, TSA and NaB induce a very
significant decrease in ABCB1 expression in H69VP drug-resistant
cells (Figure 1A, right). Significant changes can be noted after 8h
of treatment (52% inhibition with TSA, Po0.0001; 59% inhibition
with NaB, P¼0.0003) and 24h of treatment with both drugs (87%
inhibition with TSA, Po0.0001; 83% inhibition with NaB,
P¼0.0001). P-glycoprotein expression on cell membranes was
analysed by flow cytometry on TSA-treated cells. H69WT and
H69VP cells were incubated with or without 330nmoll
 1 TSA for
12h and left for a further 48h period in TSA-free medium. This
TSA treatment does not result in significant changes in P-gp
expression in H69WT cells (98% negative cells in TSA-treated or
-untreated cells), whereas a decrease in this expression is observed
in H69VP cells (Figure 1B), either when data are expressed as
percent of P-gp-positive cells (76% þve cells in control cells, 55%
þve cells in the presence of TSA) or as mean fluorescence index in
these positive cells (39 vs 29 respectively), suggesting that ABCB1
gene silencing observed in these drug-resistant cells after TSA
treatment could effectively result in inhibition of P-gp expression
at the cell membrane level.
TSA-induced ABCB1 modulation occurs at a
transcriptional level
To investigate the mechanisms implicated in these up- or
downregulations, we first addressed the question whether ABCB1
expression is directly regulated by TSA in H69 cells. To this end,
H69WT and H69VP cells were pretreated for 1h with the protein
synthesis inhibitor CHX at 10mgml
 1 followed or not by treatment
with 330nmoll
 1 TSA for 24h. Cycloheximide alone increased
ABCB1 mRNA levels in both H69WT and H69VP cells (7-fold
increase, P¼0.002, and 1.5-fold increase, P¼0.02, respectively)
(Figure 2A and B). When TSA was added, ABCB1 mRNA
modulation still occurred in both H69WT and H69VP cells in
the presence of CHX. However, CHX induced a partial but
significant inhibition of these modulations (Figure 2C). Thus,
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Figure 1 Trichostatin A (TSA) effects on ABCB1 gene in H69 cells. (A) ABCB1 expression in H69WT (left) and H69VP (right) cells treated with TSA
(330nmoll
 1) or sodium butyrate (NaB, 5mmoll
 1) for 8, 12, and 24h. (B) Decrease in P-gp membrane expression in H69VP cells treated with TSA.
Fluorescence-activated cell sorting analysis was performed with 15D3-PE antibody on H69WT and H69VP cells treated or not with TSA. Dashed line,
control cells; solid line, TSA-treated cells. ABCB1 expression was normalised against 18S RNA expression (A). Quantitation of the relative changes in gene
expression was measured by real time RT–PCR (mean7s.e.m. of 3–6 independent experiments).
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effect on ABCB1 expression. These results suggest that TSA
modulates ABCB1 expression by a direct effect on chromatin,
possibly by promoting recruitment of a repressor factor to ABCB1
promoter, as well as through the modulation of regulatory proteins
expression. Among these, WTH3 was reported to play a negative
role in ABCB1 gene expression. Moreover, WTH3 gene expression
seemed to be regulated by epigenetic mechanisms (Tian et al,
2005). However, TSA induced an overexpression of WTH3 in both
cell lines with a more important increase in drug-sensitive cells
where ABCB1 expression was upregulated (Figure 2D). These
results suggest that WTH3 was probably not a key element in TSA-
induced ABCB1 inhibition in H69VP cells. To analyse the effects
of TSA on ABCB1 transcription, H69WT and H69VP cells were
incubated with the RNA synthesis inhibitor ActD at 5mgml
 1
for 30min before TSA treatment (330nmoll
 1 for 24h).
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Figure 2 ABCB1 up- or downregulation by trichostatin A (TSA) occurs through a transcription-dependent mechanism. (A) Expression of ABCB1 in cells in
presence of TSA, cycloheximide (CHX), or actinomycin D (ActD). Cells were pretreated with CHX (10mgml
 1, 1h) or ActD (5mgml
 1, 30min) before
incubation in the presence or absence of TSA (330nmoll
 1, 24h). PCR reactions were interrupted in the exponential phase and PCR products were
electrophoresed in 2.5% agarose gel stained with ethidium bromide. (B) Expression of ABCB1 in cells treated with CHX or ActD alone. H69WT and H69VP
cells were incubated in presence or absence of CHX (10mgml
 1, 1h) or ActD (5mgml
 1, 30min). (C) Quantitation of ABCB1 expression changes in cells
treated with TSA (hatched bars) or not (open bars) in the presence or absence of CHX or ActD. Cells were treated as in (A). (D) WTH3 expression in
H69 cells treated with TSA (330nmoll
 1). ABCB1 expression was normalised against 18S RNA expression. Quantitation of the relative changes in ABCB1
expression was measured by real time RT–PCR. WTH3 expression was normalised against GAPDH RNA expression. Relative changes in WTH3 expression
were measured by classical RT–PCR (mean7s.e.m. of three independent experiments). *Po0.05.
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ABCB1 expression in H69WT and H69VP cells (Figure 2A and C).
These data suggest that TSA regulates ABCB1 expression at the
transcriptional level. However, regulation of mRNA abundance
can also occur at the level of RNA degradation. To examine if
modifications of RNA stability could also account for TSA effects
on ABCB1 mRNA levels, H69WT and H69VP cells were pretreated
with ActD at 5mgml
 1 to block new RNA synthesis. Then, the cells
were treated or not with 330nmoll
 1 TSA. ABCB1 mRNA half-lives
appeared almost identical in both H69WT and H69VP cells, and
TSA treatment did not significantly change these mRNA stabilities
(Figure 3A and B). Finally, we examined if TSA could change
ABCB1 mRNA degradation through transcriptional modulation of
other genes implicated in mRNA stability. For this purpose,
H69WT and H69VP cells were incubated with or without
330nmoll
 1 TSA for 6h before ActD treatment for 30min at
5mgml
 1. ABCB1 mRNA was then analysed immediately and 12h
later. ABCB1 mRNA level decreased of about 40% after 12h in
H69WT cells, whether or not they were pre-incubated with TSA.
Similar decreases of about 30% were observed in H69VP cells
(Figure 3C). Thus, TSA modulates ABCB1 mRNA transcription
both in H69WT and H69VP cells without influencing its
degradation.
TSA increases the overall acetylation of histones but
differentially modulates H3 and H4 acetylation levels at the
ABCB1 promoter level in sensitive and resistant cells
The biological consequence of HDACs inhibition is the accumula-
tion of acetylated histones. To verify the activity of TSA in our
study, H69WT and H69VP cells were treated with 330nmoll
 1
TSA for up to 24h, and histones were analysed by AUT-
polyacrylamide gel electrophoresis (PAGE) (Figure 4A). The main
changes observed, both in H69WT and H69VP cells, were an
increase in H4 and H3 acetylation, particularly at the H3.3 and
H3.2 levels, together with an increase in H2A and H2B acetylation.
On the contrary, H1 remains unaffected by TSA, as this histone
form cannot be acetylated through post-translational processes
in vivo (Alvelo-Ceron et al, 2000). To confirm these data, the
acetylated histone H3, acetylated histone H4 and methylated H3K9
levels were determined by western blotting. Consistent with
previous observations, we found that TSA increased the acetylated
histone H3 and H4 without any change in methylated H3K9 in
both H69WT and H69VP cells (Figure 4B). To further analyse the
implications of these histone acetylation changes on ABCB1
expression, we performed ChIP assays to determine histone
acetylation within specific regions of the ABCB1 promoter. Primer
sets encompassing ABCB1 proximal (þ292 to þ591) and distal
( 981 to  817) promoter regions were used to map changes in
histone acetylation following TSA treatment. In comparison with
H69WT drug-sensitive cells in which the ABCB1 gene is under-
expressed, H69VP drug-resistant cells had increased H4 acetyla-
tion in both regions (about twofold) and increased H3 acetylation
(about 2.5-fold) in the proximal region of the promoter. H3K9
methylation levels appeared similar in H69WT and H69VP cells
(Figure 5A). Following TSA treatment at 330nmoll
 1 for up to
24h, H4 acetylation progressively increased at both promoter
regions in the two cell lines (Figure 5B). The increase in H4
acetylation levels was lower in the resistant cells, probably due to
the basal hyperacetylation of histone H4 in these cells at both
promoter regions (Figure 5A). An increased H3 acetylation was
also observed in H69WT cells. However, in H69VP cells, TSA
induced an only transient H3 hyperacetylation, with a 2- to 4-fold
increase after 8h treatment and a return towards basal levels after
24h (Figure 5C). If we consider the fold difference in basal H3
acetylation between drug-sensitive and drug-resistant cells (about
2.5-fold in the proximal region and no difference in the distal
region), we can notice that histones H3 in H69VP drug-resistant
cells are approximately twice as hyperacetylated as in H69WT
drug-sensitive cells after 8h treatment with TSA. The histone H3
deacetylation after 24h treatment was not observed by western
blotting of total nuclear histone H3 (Figure 4B), suggesting that
this phenomenon remains localised. Trichostatin A treatment did
not modify H3K9 methylation status at both promoter sites in
H69WT or H69VP cells (Figure 5D). These results show that, as
expected, the transcriptional activation of ABCB1 induced by TSA
in H69WT drug-sensitive cells was associated with hyperacetyla-
tion of histones H3 and H4 at ABCB1 promoter. On the contrary,
hyperacetylation of histones H3 and H4 observed in H69VP drug-
resistant cells after 8h treatment with TSA was associated with
ABCB1 gene silencing (Figure 1A).
ABCB1 repression by TSA appears independent of DNA
methylation status and MBD1 recruitment in H69VP cells
ABCB1 expression has been shown to be regulated not only by
histone acetylation, but also by DNA methylation. ABCB1
promoter contains several GC boxes, which appear essential for
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Figure 3 ABCB1 up- or downregulation by trichostatin A (TSA) is not mediated by mRNA stability changes. (A) Analysis of a transcription-independent
TSA effect on ABCB1 mRNA stability in H69WT cells. Cells were treated with 5mgml
 1 actinomycin D (ActD) 30min before the addition of 330nmoll
 1
TSA. Cells were harvested immediately or as indicated. (B) Analysis of a transcription-independent TSA effect on ABCB1 mRNA stability in H69VP cells.
Cells were treated and harvested as in (A). (C) Analysis of a transcription-dependent TSA effect on ABCB1 mRNA stability. H69WT and H69VP cells were
pretreated with 330nmoll
 1 TSA for 6h before the addition of ActD (5mgml
 1, 30min). Cells were harvested immediately or 12h later for ABCB1 mRNA
quantitation. ABCB1 expression was normalised against 18S RNA expression. Quantitation of the relative changes in ABCB1 expression was measured by
real time RT–PCR (mean7s.e.m. of three independent experiments). *Po0.05.
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highly relevant as they seem to be binding sites for ABCB1
activators and repressors. The methylation profiles of these two
boxes have been analysed by methylation-specific PCR in H69WT
and H69VP cells and compared with those from hypermethylated
(MCF7 cells) or hypomethylated (peripheral blood mononuclear
cells, PBMCs) controls. The  50GC and  110GC boxes appeared
hypomethylated in both cell lines (Figure 6A). This hypomethyla-
tion of ABCB1 promoter was confirmed by a COBRA analysis of
the þ4 cytosine-phosphate-guanine (CpG) site of the Inr region.
Both cell lines appeared to display hypomethylated ABCB1 DNA
(Figure 6B). These data confirm the sensitivity of hypomethylated
ABCB1 promoter to the direct action of HDACs (El-Osta et al,
2002). Treatment of H69WT and H69VP by TSA (330nmoll
 1,
24h), or the demethylating agent 5azadC (2mmoll
 1, 72h), or a
combination of both (cells treated with 5azadC for 72h were
resuspended in fresh supplemented medium and harvested 33h
later. Trichostatin A treatment was applied during the last 8 or
24h), did not influence significantly methylation status of these
various promoter sites (Figure 6A and B), indicating that ABCB1
gene modulation, induced by TSA in both cell lines, does not result
from alterations in the methylation status of the ABCB1 promoter.
Finally, although treatment with 5azadC alone induced a
significant increase in ABCB1 expression in H69WT cells (about
2.5-fold increase, data not shown), it did not modulate TSA-
induced upregulation of ABCB1 expression in H69WT. Similarly,
in the H69VP drug-resistant cells, the combined treatment with
TSA and 5azadC did not enhance the level of ABCB1 down-
regulation, except for 24h treatment with TSA (Figure 6C),
probably in relation with the activation of a repressor of ABCB1
transcription. Thus, the low level of ABCB1 promoter methylation
we observed in H69WT and H69VP cells, or other methylated
sequences outside GC boxes and Inr element analysed, do not
appear critical for TSA action on ABCB1 mRNA expression in
these cells containing originally a hypomethylated ABCB1
promoter. It has been reported that MBD1, a protein associated
with methylation-dependent repression, could also bind non-
methylated DNA (Baker and El Osta, 2004). Thus, MBD1 binding
to the inverted CCAAT box ( 79 to  75) of the ABCB1 promoter
was evaluated in H69VP cells by ChIP using an anti-MBD1
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 1, 18h) did not
induce any significant change in MBD1 recruitment on the
promoter site (Figure 7A), suggesting that the ABCB1 expression
decrease observed in H69VP cells was not linked to a MBD1-
mediated methylation-independent silencing.
TSA treatment results in similar PCAF binding to ABCB1
promoter CCAAT inverted box in both cell lines
Histone deacetylases inhibitors induce ABCB1 transcription
through the association of the NF-Y factor with the CCAAT
inverted box and the PCAF HAT recruitment (Friedman et al,
2002). To determine the role of this process in the ABCB1
regulations induced by TSA in H69 cells, the chromatin from
H69WT and H69VP cells, treated or not with 330nmol/LTSA for
24h, has been immunoprecipitated by anti-PCAF antibody. The
immunoprecipitated DNA was analysed by PCR using primers
corresponding to the inverted CCAAT box promoter region. Before
TSA treatment, PCAF binding to the ABCB1 promoter appeared
similar in H69WT and H69VP cells (Figure 7B). This suggests that
basal ABCB1 overexpression observed in H69VP cells does not
result from an increased PCAF protein binding. Incubation of cells
with TSA for 24h resulted in an increase in PCAF recruitment in
both cell lines (2- to 3-fold increase) without any significant
difference between H69WT and H69VP cells response (Figure 7C).
Then PCAF recruitment occurred at the ABCB1 promoter level
during TSA treatment, whether this treatment resulted in an up- or
downregulation of the corresponding gene.
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Figure 5 Trichostatin A induces differential temporal histone acetylation at the ABCB1 promoter level. (A) Relative level of H3 acetylation, H4 acetylation,
and H3K9 dimethylation at the proximal and distal regions of the ABCB1 promoter in untreated H69WT (hatched bars) and H69VP cells (black bars). Fold
change in acetylated H4 (B), acetylated H3 (C), and dimethylated H3K9 (D) at the proximal and distal regions of the ABCB1 promoter in H69WT (hatched
bars) and H69VP (black bars) cells treated with TSA (330nmoll
 1, 8, and 24h). PCR amplifications of ChIP samples (mean7s.e.m. from three independent
experiments). *Po0.05.
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Epigenetic mechanisms (histone acetylation, DNA methylation)
have been shown to play a pivotal role in ABCB1 gene expression
in several tumour cell systems (El-Osta et al, 2002; Labialle et al,
2002; Scotto, 2003).
Results presented here show that HDAC inhibitors TSA and NaB
increased ABCB1 gene expression in H69WT drug-sensitive cells,
but strongly inhibited its expression in H69VP drug-resistant cells
at both the mRNA and protein levels. H69 cells constitutively
express the ABCC1 drug transporter, with an overexpression in
H69VP cells. ABCC1 TATA-less gene promoter shares common
regulatory elements with ABCB1 (eg GC boxes, Sp1 binding site,
putative AP-1 site). Interestingly, TSA also downregulated this
ABCC1 gene expression in H69VP drug-resistant cells (data not
shown). Thus, our results support the idea that HDAC inhibitors
could modulate MDR through simultaneous inhibition of different
ABC transporters as recently suggested for 4-phenylbutyrate
(Ammerpohl et al, 2007).
Simultaneous treatments with the transcription inhibitor ActD
suggested that these up- and downregulations occurred at the
transcriptional level without any change in mRNA stability as
reported in leukaemic cells (Yague et al, 2003). De novo protein
synthesis inhibition with CHX did not suppress TSA-mediated
ABCB1 modulations, suggesting that TSA influence mainly this
gene transcription directly at the chromatin level. However, as
C
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Figure 6 Trichostatin A (TSA)-induced up- and downregulations of ABCB1 expression appear independent of ABCB1 promoter methylation. (A)
Methylation-specific PCR of ABCB1  50GC and  110GC boxes. Primer sets are designed to amplify methylated (M) and unmethylated (U) alleles. A
primer set encompassing both M and U whole GC region (T) was used as loading control. Left lane, MSP analysis in H69WT and H69VP cells treated with
TSA for up to 24h. Right lane, MSP analysis in H69WT and H69VP cells treated with TSA for 8h, 5azadC for 72h, or combination of both. MCF7 cells and
peripheral blood mononuclear cells (PBMC) were used as positive controls for methylated and unmethylated alleles, respectively (central lane).
Representative experiment from a series of three. (B) Combined bisulphite restriction analysis of the Inr ABCB1 promoter region in H69WT and H69VP
cells treated with TSA, 5azadC, or a combination of both. Figures represent the methylation percentages observed in the different samples (mean of two
separate independent experiments). MCF7 cells and PBMC were used as positive controls for methylated and unmethylated Inr site, respectively. (C) ABCB1
mRNA expression in H69WT (left) and H69VP (right) cells treated with TSA alone or in combination with 5azadC. ABCB1 expression was normalised
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of the transcription of other genes implicated in ABCB1 regulation
could occur as well. Among these, WTH3 was shown to be
upregulated by TSA in MCF7/Adr cells resulting in an inhibition of
MDR1 expression (Tian et al, 2005). Despite a similar increase in
WTH3 expression in H69VP cells, this factor may not be a good
candidate for ABCB1 inhibition by TSA as WTH3 is also
upregulated in TSA-treated H69WT cells exhibiting an increase
in ABCB1 expression. These conflicting results might be related to
different methylation status observed in H69 or MCF7 cells (David
et al, 2004). Cycloheximide alone appeared able to increase the
basal ABCB1 expression in H69 cells. This increase, which has
already been described for other genes (Keller and Kneissel, 2005),
could suggest that ABCB1 expression would be controlled by
short-lived repressor, or that CHX might directly stimulate ABCB1
gene transcription as reported for a-1B adrenergic gene (Hu and
Hoffman, 1993). In drug-sensitive cells, several studies have
reported an increase in ABCB1 expression by HDAC inhibitors,
a phenomenon we also observed in H69WT cells. For instance,
ABCB1 gene was overexpressed in SW620 colon carcinoma and
CEM-Bcl2 cells exposed to TSA (Jin and Scotto, 1998; Baker et al,
2005), or KU812 and NB4 cells exposed to depsipeptide (Tabe et al,
2006; Yamada et al, 2006). In drug-resistant cells, HDAC inhibition
also increased ABCB1 expression in CEM-A7R, Kasumi-1, and
Kasumi-6 cell lines (El-Osta et al, 2002; Tabe et al, 2006). On the
contrary, our results showed a repression of ABCB1 gene
expression by TSA and NaB. Direct inhibition of ABCB1
expression by HDAC inhibitors in drug-resistant cells appeared
as a relatively uncommon event, previously reported in murine
L1210R cells (Castro-Galache et al, 2003).
To better understand the mechanisms of ABCB1 regulation in
H69 cells, we have investigated the effect of HDAC inhibition by
TSA on histone post-translational modifications, focusing on H3
and H4 acetylation, and H3K9 methylation. We found that even
though TSA increased global accumulation of acetylated histones,
H3 and H4 acetylation displayed different temporal patterns at the
ABCB1 promoter level. Histone deacetylases inhibitors increase H3
and/or H4 acetylation at the promoter of activated genes such as
TbRII (Zhao et al, 2003), IAP (Hinnebusch et al, 2003), or Mn-SOD
(Maehara et al, 2002). We observed the same phenomenon in
H69WT drug-sensitive cells both at distal and proximal regions of
the ABCB1 promoter. Examining the downstream þ292 to þ591
region of the gene give data on the histone modification of the
transcribed part of the gene and therefore on possible regulation
of elongation by histone modification. Concerning the  981 to  817
region, the T-cell factor-4 (TCF4)/b-catenin complex has been
reported as an ABCB1 transcriptional activator which binds seven
elements spanning the  1813 to  261 sequence of the ABCB1
promoter. The  981 to  817 region harbours one of these seven
TCF elements (Yamada et al, 2000). It has been recently suggested
that TCF4 plays an important role in the carcinogenesis of lung
cancer as demonstrated by its high expression in cancer samples
(Li et al, 2005). Besides, overexpression of b-catenin reported
in lung cancer and Wnt signalling pathway, which results in
b-catenin stabilisation and activation, is found to be aberrantly
activated in lung cancer (Mazieres et al, 2005). Hence, examining
the acetylation status of the  981 to  817 region of the ABCB1
promoter seemed interesting in the H69 lung carcinoma cell lines.
Changes in H3 and H4 acetylation were rapid (within 8h) and
directly correlated with ABCB1 induction. Similar data have been
reported in NB4 cells incubated with FK228 (Tabe et al, 2006), or
in CEM-Bcl2 cells treated with daunorubicin (Baker et al, 2005).
In TSA-treated H69VP cells, H4 acetylation exhibited the same
kinetics than in drug-sensitive cells, in spite of the repression of
the ABCB1 gene induced. Furthermore, H3 acetylation displayed a
biphasic curve with a transient hyperacetylation followed by a
decrease in this acetylation level. Interestingly, TSA-mediated
decrease in ABCB1 mRNA occurred rapidly after 8h when both H3
and H4 displayed a hyperacetylated pattern at the gene promoter
level. Similar gene inhibition by TSA in spite of H4 acetylation at
the promoter level has already been described for PU.1 gene
(Laribee and Klemsz, 2001). Several hypotheses can be proposed to
explain this unexpected phenomenon: a nucleosome displacement
induced by histone acetylation could result in masking of critical
DNA activation sites (Laribee and Klemsz, 2001), or the gene
repression could be linked to the acetylation by TSA of non-
histone proteins implicated in gene transcription (Wilson et al,
2002; Mulholland et al, 2003). In H69VP cells, after 24h of TSA
treatment, H3 acetylation decreases whereas H4 acetylation
continues to increase. This H3 deacetylation cannot be explained
by TSA degradation or efflux as global hyperacetylation remains
high at the whole nucleus level. This decrease in acetylated H3
might be linked to nucleosomes loss instead of H3 deacetylation
(Deckert and Struhl, 2001), but this seems rather unlikely as this
loss would result in concomitant decrease in acetylated H4 level.
Deacetylation following a transient hyperacetylation of H3 and/or
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Figure 7 Trichostatin A (TSA)-induced inhibition of ABCB1 expression in H69VP cells appears independent of MBD1 and PCAF binding to the ABCB1
promoter CCAAT inverted box. (A) Chromatin immunoprecipitation analysis of MBD1 binding in H69VP cells treated with TSA (330nmoll
 1) for 18h.
(B) Chromatin immunoprecipitation analysis of PCAF binding in untreated H69WT and H69VP cells. (C) Relative changes in PCAF binding in H69WT and
H69VP cells treated with TSA (330nmoll
 1) for 24h. *Significantly different from untreated controls. Po0.05 (mean7s.e.m. from three independent
experiments).
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mammary tumour virus and c-jun promoters (Thompson et al,
2001; Mulholland et al, 2003), and even ABCB1 promoter in CEM-
Bcl2 cells (Baker et al, 2005). Nevertheless, it should be noted that
the H3 acetylation level observed after 24h TSA in H69VP cells was
always above the basal value measured in untreated cells. Thus, H3
acetylation decrease could help or maintain ABCB1 silencing, but
would probably not act as a starting event of the process.
In addition to histone post-translational modifications, DNA
methylation is one of the mechanisms controlling ABCB1
transcription with an inverse relationship between promoter CpG
methylation and ABCB1 expression (Kantharidis et al, 1997;
Nakayama et al, 1998; El-Osta et al, 2002). However, as we
observed promoter hypomethylation in H69WT cells, ABCB1
repression in drug-sensitive cells seems independent of its
promoter methylation, a phenomenon previously reported in
SW620 cells (Jin and Scotto, 1998; Baker et al, 2005). In H69 cells,
TSA induces up- or downregulation of ABCB1 without any
significant modification of its promoter methylation status, as
already observed in CCRF-CEM cells (El-Osta et al, 2002). It has
been reported that ABCB1 activation by HDACs can only occur
when its promoter is demethylated, either spontaneously or after
treatment with demethylating agent 5azacytidine (El-Osta et al,
2002). In a similar way, in H69WT cells, TSA alone can induce
ABCB1 expression since its promoter appeared hypomethylated
and simultaneous incubation with 5azadC did not potentiate gene
expression, as observed in hypomethylated CEM-Bcl2 and SW620
cells (Baker et al, 2005). 5azadC alone induced moderate ABCB1
expression suggesting either a possible further slight demethyla-
tion of an already hypomethylated ABCB1 promoter (as observed
by COBRA analysis of the Inr sequence), or the demethylation of
the promoter of other gene(s) implicated in ABCB1 activation. Our
results in H69VP drug-resistant cells demonstrate that TSA could
induce ABCB1 silencing in a hypomethylated promoter environ-
ment. This effect could be linked to the induction of an increase in
DNA methylation level as it has been reported that NaB was able to
increase this level in several cell lines (DeHaan et al, 1986;
Cosgrove and Cox, 1990). Nevertheless, our results showed that
ABCB1 repression by TSA in H69VP cells was not associated with a
hypermethylation of its promoter at the analysed sites. Further-
more, it has been suggested that MBD1 protein could play a role in
ABCB1 methylation-independent silencing (Baker and El Osta,
2004). The lack of MBD1 recruitment following TSA treatment
argues against this possibility in H69VP-resistant cells.
To further elucidate possible mechanisms of TSA-mediated
ABCB1 regulations in H69 cells, the ChIP assay was performed to
determine if PCAF binding to ABCB1 promoter differs between
drug-sensitive and drug-resistant cells and if PCAF occupancy
changes following HDAC inhibition by TSA in these two cell lines.
This protein, which possesses a HAT activity, can therefore
activate basal or induced expression of ABCB1 gene (Hu et al,
2000; Friedman et al, 2002; Tanaka et al, 2003). Moreover, ABCB1
promoter is activated by PCAF overexpression (Jin and Scotto,
1998), but a direct association of PCAF with ABCB1 promoter in
vivo has not been previously demonstrated. Our results show that
PCAF is bound to the ABCB1 promoter in a similar extent in drug-
sensitive and drug-resistant cells and reveal similar increases in the
level of bound PCAF in TSA-treated H69WT or H69VP cells. These
results suggest that the levels of PCAF binding to ABCB1 promoter
in vivo do not correlate with gene expression level in H69 drug-
sensitive and drug-resistant cells, unlike NF-Y binding in SSC cells
(Okamura et al, 2004). The increase in PCAF binding upon TSA
treatment in H69WT cells fits well with previous reports on the
role of this protein in ABCB1 induction. However, the silencing of
ABCB1 gene by TSA in H69VP cells was accompanied by a similar
increase in PCAF recruitment to the promoter inverted CCAAT
box region. This suggests that the ABCB1 gene repression induced
by TSA in drug-resistant cells occurs independently of PCAF
binding.
Taken together, our data provide evidence that HDAC inhibition
can result in differential regulation of the ABCB1 gene according to
the resistance status of the SCLC H69 cells (Figure 8). Although a
definite unique regulatory mechanism cannot be drawn from these
results, they suggest that these regulations occur at a transcrip-
tional level. The fact that ABCB1 will be up- or downregulated in
H69 cells appears independent of the methylation of the ABCB1
 50GC,  110GC, and Inr promoter sites, and of MBD1 and PCAF
binding, but is associated to different temporal patterns of histone
acetylation at the ABCB1 promoter level. Whereas the CCAAT
inverted box plays a pivotal role in ABCB1 upregulation by HDAC
inhibitors, it seems that their repressive effect on this gene
expression originates outside this element. Although TSA is not in
in H69WT
in H69VP
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Figure 8 Pathways summary: trichostatin A modulates ABCB1 gene expression in H69 cells (increase in H69WT cells but decrease in H69VP cells). This
differential modulation occurs both through a direct action on chromatin and through changes in regulatory factors expression (1). Among these, WTH3
does not play a key role. This modulation occurs through transcriptional mechanisms (2) and is not linked to alterations in RNA stability (3). It is concomitant
with differential histone acetylation patterns at the ABCB1 promoter (4), but appears independent of DNA methylation and MBD1 (5) or PCAF recruitment
(6) on CCAAT inverted box. Dashed lines represent pathways that cannot explain the differential regulation of ABCB1 expression in H69WT and H69VP
cells.
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might be chemosensitising agents and promising drugs for
combinatorial treatments with classical chemotherapeutic drugs.
The characterisation by reporter constructs of the promoter
sequences required for these up- and downregulations of ABCB1
in H69 cells is currently under investigation in our laboratory to
identify trans-regulatory factors mediating this differential TSA
effect.
Most drug-resistant lung cancers overexpress both P-gp and
MRP1 proteins (Triller et al, 2006). H69VP-resistant cells exhibit
upregulation of both MDR proteins, somehow reflecting situations
commonly seen in clinic. In this sense, the choice of this cell model
seems appropriate. However, ABCB1 promoter of H69VP cells is
constitutively strongly hypomethylated, and the downregulation of
ABCB1 expression by HDAC inhibition could require such low
level of DNA methylation in ABCB1 promoter. Indeed, we have
previously shown that ABCB1 expression remains unchanged after
TSA treatment of the multidrug-resistant human ovarian adeno-
carcinoma cell line OV1/VCR, in which ABCB1 promoter is slightly
hypermethylated compared to its sensitive IGROV1 counterpart
(Yatouji et al, 2007). Further methylation analysis on different cell
lines and clinical samples is required to clarify the relevancy of
basal methylation status of ABCB1 promoter on ABCB1 repression
by HDAC inhibitors.
Despite these limitations, this unique cellular model, which can
display HDAC-mediated up- or downregulation of ABCB1 gene
according to resistance status, appears therefore useful for effective
design of agents to reverse MDR in cancer patients.
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